Relationship between the Heparin Management Test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 3, 2001, Pages 217-221

  Tsimikas, S ^a   Beyer, R ^a   Hassankhani, A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Activated clotting time (ACT); Angioplasty; Heparin; Heparin management test (HMT)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DEVICE; HEALTH CARE COST; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD COAGULATION TESTS; COHORT STUDIES; DRUG MONITORING; HEPARIN; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 0035175416     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011908803939     Document Type: Article

References (22)

1. Activated coagulation time of whole blood
2. Antithrombotic therapy in patients undergoing coronary angioplasty
3. The use of activated clotting times of monitor heparin therapy during and after interventional procedures
4. Adequate heparinization during PTCA: Assessment using activated clotting times
5. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty
6. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
7. When we "act" on ACT levels: Activated clotting time measurements to guide heparin administration during and after interventional procedures
8. Relation between activated clotting time during angioplasty and abrupt closure
9. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials
10. Statistical methods for assessing agreement between two methods of clinical measurement
11. Comparing methods of measurement: Why plotting difference against standard method is misleading
12. Heparin management test versus activated coagulation time during cardiovascular surgery: Correlation with anti-Xa activity
13. Heparin detection by the activated coagulation time: A comparison of the sensitivity of coagulation tests and heparin assays
14. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin
15. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty
16. Whole blood coagulation analyzers
17. Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation
18. The heparin management test: A new device for monitoring anticoagulation during coronary intervention
19. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty
20. Novel inhibitors of factor X for use in cardiovascular diseases
21. Reliability of the heparin management test for monitoring high levels of unfractionated heparin: In vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass
22. Evaluation of a new point of care heparin test for cardiopulmonary bypass: The TAS heparin management test